ocr: Figure 4 Bone mineral density - Femoral neck Least squares means of percentage change from baseline All randomized patients with at least one post-baseline assessment available with last post-baseline observation carried forward 6 51 4 - - AB,CvsP:p p<0.05 AB,CDVSP:pe0.05 A.B,CDvsP:p<0.05 3 2 AvsP:p<0.05 l J Week 26 Week 52 Week 78 Week 104 Treatment duration Vivelle 0.1 mg/day (A) ---- Vivelle 0.05 mg/day (B) - - - Vivelle 0.0375 mg/day (C) * -Vivelle 0.025mg/day (D) * Placebo (P)
